Group items tagged

Have you ever wanted to know how vaccines are sent out from a lab to your doctor's office safely? Well, believe it or not, the integrity of the vaccines relies on how they have been packed just as much as how they are being transported. And the entire process is not as simple as you may think. Traditionally, styrofoam boxes might work well to secure glass or delicate goods during transportation but when it comes to hauling vials of liquid vaccine solutions out to medical centres and hospitals; the packing process must be more rigorous-understandably. The integrity of the vaccines, being transported, must adhere to particular protocols from the second they are packed right up to the moment they are administered. This process sounds strict and that's because it is. If vaccines are not well-cared for, even during transit, then they are at risk of being contaminated or damaged therefore rendering them unusable. Incorrectly transporting vaccines, which will end up being destroyed, is something nobody wants to happen therefore vaccine transportation must be strict. One of the best ways to ensure the safe and efficient transit of medical goods, like vaccines, is by using bioprocess containers. These containers are specifically designed to maintain the integrity of sensitive biological materials throughout their journey.

A recently published report on medicines optimisation highlights the urgent need for transformative changes across all pharmacies to unlock their full potential in delivering integrated care. The report by Public Policy Projects (PPP) is first of the four in the series that emphasises the significant benefits that medicines optimisation can bring to integrated care systems (ICSs). This includes reducing health inequalities and improving population health. Pointing to the "untapped opportunity" that medicines optimisation presents for ICSs facing financial challenges, the report underscores the vital role of pharmacies in enhancing patient outcomes. The launch of the Pharmacy First services has already demonstrated the essential contribution of pharmacies to the health and care system. With "medicines being the second highest cost to the NHS," the report recommends ways "to achieve better value for money while improving patient outcomes".

Wes Streeting's speech at the Labour Party Conference 2024 outlines several key health and social care reforms, which hold significant implications for community pharmacy in England. His focus on reforming and rebuilding the NHS to ensure fair, universal access to care, with prevention and early intervention at its core, presents both opportunities and challenges for community pharmacy. Here are the potential implications: 1. Prevention Focus Streeting's vision of a shift from a reactive, hospital-based model to a preventive healthcare system presents a promising future for community pharmacies. These changes could significantly reduce pressures on GPs and hospitals, integrating pharmacies more closely into primary care networks and enhancing their role in preventive care. 2. Digital Transformation The move from an "analogue to digital" NHS could see community pharmacies adopting more digital tools and systems for service delivery. This would likely involve greater use of digital prescribing, telehealth consultations, and AI-driven services. Pharmacies will need to invest in digital infrastructure and ensure that pharmacy professionals are trained to operate within a more tech-centric environment. 3. Reform and Redistribution of Services Streeting's plans to extend choice and equitable access to services mean that community pharmacies could become integral to providing care in underserved or disadvantaged areas. With a focus on decentralising healthcare and bringing it closer to local communities, community pharmacies could play a more significant role in supporting healthcare delivery in areas where GP services are stretched. This may include expanding access to pharmacy services in the most deprived areas, aligning with Labour's emphasis on addressing health inequalities.

As part of its commitment to enhancing business performance and ensuring safe, effective pharmaceutical care, Numark has developed 12 guiding principles to help its members in adapting to evolving skill sets and shaping their future. Numark's future model for community pharmacy practice presents an ambitious vision for the sector, focusing on delivering a range of clinical services, enhancing the health of local populations, and becoming an integrated part of primary care. Harry McQuillan, Chairman of Numark, reveals that these principles were derived from changes in pharmacy education, such as the integration of prescribing into undergraduate courses. He views these principles as a formal recognition of the skills that pharmacists and pharmacy teams have developed over time, particularly in the area of independent prescribing. "These principles formalize those evolving capabilities of pharmacists, especially in independent prescribing," McQuillan tells Pharmacy Business.

The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The diagnostics advisory committee, a standing advisory committee of NICE, agreed that it should be possible to gather samples for genotype testing at a location that is convenient for the person having the test and highlighted the role of pharmacies as accessible locations for CYP2C19 genotype testing.The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The d

The business landscape worldwide is undergoing a significant transformation, shifting from a sole focus on profitability to incorporating a broader spectrum of considerations. Today, Environmental, Social, and Governance (ESG) criteria are integral to business operations, reflecting a commitment to sustainable and ethical practices alongside financial growth. ESG stands for three interconnected pillars: Environmental, focusing on reducing a company's ecological footprint; Social, addressing the impact on employees, diversity, equity, inclusion, and the broader community; and Governance, which ensures responsible management practices, ethical behavior, and compliance with regulations. This holistic approach is becoming a critical foundation for long-term success in various industries, including healthcare. For the UK healthcare and pharmacy sectors, integrating ESG not only aligns with global sustainability goals but also offers substantial benefits. This article delves into the specific implications of ESG for UK pharmacies, highlighting how they can leverage these practices to foster both community well-being and business success.

In its closing oral statement to the UK Covid Inquiry Module 3 on Wednesday (27 November), the National Pharmacy Association (NPA) urged the government and NHS to "recast community pharmacy in their minds as a valuable partner in the post-pandemic recovery, and not as a cost center." The Inquiry was also asked to recommend sufficient government investment in the network and infrastructure needed to integrate community pharmacy into the broader health system and support effective cooperation across the health service. Additionally, the NPA requested that the significant contribution of community pharmacy to the pandemic response be reflected in the Module 3 findings to "redress the lack of recognition they received throughout the pandemic." The NPA's closing statement addressed four key issues - the role of community pharmacy, the impact on pharmacy teams, the resilience of the pharmacy network, and the lack of recognition given to the sector during the pandemic and since. Lee John-Charles, speaking for the NPA, told the Inquiry that "Community pharmacy became the first port of call for patients seeking health advice during the pandemic." "Many community pharmacies went to great and heroic lengths to ensure that their services were maintained during the pandemic and demonstrated the value of the network of community pharmacies across the country."

Community pharmacists involved in the Independent Prescribers Pathfinder Programme will be able to generate NHS prescriptions through the NHS Electronic Prescription Service (EPS). NHS England has secured a new clinical system, CLEO SOLO from Cleo Systems, to facilitate this service. The system is being rolled out to 'pathfinder' sites so they can start delivering their proposed prescribing models and pathways. Integrated Care Boards (ICBs) across England have been informed of this development and are asked to provide support and leadership to their sites throughout the programme, which will run until March 2025. NHS England will also conduct a series of webinars with ICBs to discuss the CLEO SOLO rollout. David Webb, Chief Pharmaceutical Officer at NHS England, highlighted that the Pathfinder Programme will enable community pharmacist prescribers at 'pathfinder' sites to issue NHS prescriptions for conditions such as cardiovascular and respiratory diseases. "This will help us develop a framework which will support the commissioning of independent prescribing as part of clinical services in community pharmacy in the future," Webb said.

At the Future of Britain Conference 2024, the newly appointed Secretary of Health and Social Care, (DHSC) Wes Streeting, stated that "Labour's DNA is in the NHS". He also called for a long-term approach to reform the broken health sector and the integration of artificial intelligence (AI) to steer the healthcare system towards sustainability and growth. Hosted by Tony Blair Institute for Global Change and My Life My Say today, Tuesday, 9, Streeting discussed the plans to fix the healthcare system and role of Artificial Intelligence (AI) in "making the right choices" by bringing in three essential shifts in the healthcare. Criticising the previous Conservative administration for leaving "massive burning deck issues" due to constant reshuffling within the Department of Health and Social Care (DHSC), Streeting lamented that this "instability" and "indecisions" have made comprehensive reform even more pressing. Drawing inspiration from Chancellor Rachel Reeves' speech on economic growth, Streeting stressed the interconnectedness of health and economic prosperity.

In a bid to amplify the role of pharmacists in clinical services and vaccination programs, the Pharmacists' Defence Association (PDA) has embarked on a groundbreaking collaboration with Aston University. This initiative, funded by Innovate UK Business Connect, aims to explore the feasibility and impact of integrating additional healthcare interventions within community pharmacies. "The Knowledge Transfer Partnership (KTP) research project represents an exciting opportunity to advance the role of pharmacists in patient care," remarked Alison Jones, Director of Policy at PDA. "This project will be an important part of that evolution, supporting individual pharmacists to have more opportunities to practice and so develop more fulfilling careers." Led by the PDA and Aston University, the project will commence imminently, focusing on the Priory Community Pharmacy in Dudley.

To maximise the benefits of the Pharmacy First service for patients, the NHS, and community pharmacies, Community Pharmacy England (CPE) has advised the community pharmacists to to establish a robust relationship between community pharmacies and local general practices. The news comes after several reports highlighted issues regarding GP referrals for the seven minor ailment conditions under the Pharmacy First services. According to the reports, many pharmacists claimed that "many GPs in England are not sending patients to them to be treated - and that some are refusing to participate at all in the "groundbreaking" Pharmacy First scheme". In response to foster better relationship with the GPs, CPE has said that strong local collaborations will enable general practice teams to confidently refer patients to the Pharmacy First and other community pharmacy services where appropriate. Moreover, the organisation emphasised implementation of long-term changes in practice will take time. The current focus on integrating GP referrals to Pharmacy First will likely require sustained effort over several months or longer.

The Royal Pharmaceutical Society (RPS) presented key evidence to the UK COVID-19 Inquiry on 10 September, underscoring the vital role of pharmacists and pharmacy teams during the pandemic. Deirdre Domingo, legal representative for the RPS, delivered the statement during the Module 3 public hearings, which focus on the impact of COVID-19 on healthcare systems across the UK. As the professional body representing pharmacists and pharmaceutical scientists in Great Britain, the RPS urged the Inquiry to consider several critical issues: Recognition of pharmacists as key workers The RPS highlighted the crucial role pharmacy teams played in ensuring continued access to essential medicines and their integral involvement in the roll-out of COVID-19 and flu vaccinations. However, the Society also raised concerns over significant failures and challenges, such as inadequate safety measures to protect pharmacists at work, confusing national guidance, increased hostility towards healthcare professionals, and a disparity in the treatment of community pharmacy compared to NHS staff.

In preparation for World Pharmacists Day on September 25, Pharmacy Business conducted a social media poll to explore how pharmacists can improve global health outcomes. More than 64 per cent of respondents indicated that pharmacists should prioritize promoting preventive care. Other suggestions included advancing research and development (9 per cent), increasing interdisciplinary collaboration (14 per cent), and addressing health disparities (14 per cent). This year's theme for World Pharmacists Day is "Pharmacists: Meeting Global Health Needs." The International Pharmaceutical Federation (FIP) emphasises that pharmacists are integral members of healthcare systems, playing a crucial role in meeting health needs in various ways daily.

Over the last few years pharmacy and the role of pharmacy teams has changed dramatically. The introduction of technology and the integration of artificial intelligence (AI) within systems that provide healthcare and support to pharmacies holds great promise; for improving access to health, supporting patient outcomes, and optimising operational efficiency. Currently, the potential use of AI could span the whole of the medicines value chain, from AI-driven drug discovery to personalised medicines and automated dispensing systems. However, the rapid advancement of AI technology does raise several ethical concerns. This article will explore these concerns and how they can be addressed. In previous articles, I have discussed what underpins artificially intelligent machines and the importance of data. Datasets are the foundation on which AI algorithms learn and generate conclusions. The first step to understanding the potential ethical implications of AI across the pharmacy sector is to understand the data that is held within these foundational datasets. Patient privacy and data security AI systems in and outside of the pharmacy sector, which support patient care, rely heavily on vast amounts of medical data (patient medical records, PMR data, etc). However, the collection, storage, and use of such sensitive data can possibly bring significant privacy concerns. GDPR compliance is essential within the UK and ethical questions arise around data ownership, patient consent, and the possibility of data and cybersecurity breaches. As frontline healthcare professionals, we need to be able to support our patients when questions are asked about their data. For example, how can patients be sure their data is used only for its intended purposes? Is anonymised data truly safe from de-identification techniques that could expose private information?

Pharmacy minister Stephen Kinnock has pledged to enhance the role of community pharmacies, particularly in deprived areas, by making better use of the skills of pharmacy teams. In a video message at the SIGMA UK Community Pharmacy Conference 2024 on Sunday, Kinnock also announced plans to expand the Pharmacy First initiative and introduce an independent prescribing service, making prescribing an integral part of the service delivered by community pharmacies. He said: "Since taking on the role of minister of state for care in government, my message has been very clear: we must get our fantastic primary care sector back on its feet to be able to deliver for our patients. "This government is committed to shifting care from hospital to community, from analogue to digital, and from sickness to prevention, and pharmacies will play a vital role in that." Kinnock acknowledged the pressures faced by the sector and expressed concerns that so many community pharmacies have exited the market over the past decade.

A worrying rise in pharmacy closures across England is disproportionately affecting older people and rural communities, according to a new report by Healthwatch England. Findings obtained through Freedom of Information (FoI) requests have exposed the scale of the issue, with over 436 permanent pharmacy closures recorded in 2023 and more than 13,800 temporary closures resulting in nearly 47,000 hours lost. The report, published on Thursday, paints a bleak picture of access to vital healthcare services, particularly in rural areas where pharmacy closures have hit hardest. The report found that Integrated Care Boards (ICBs) in rural areas recorded a higher level of temporary pharmacy closures compared to ICBs in predominantly urban areas. Additionally, ICBs with a higher proportion of people over 60 years of age recorded a higher number of hours lost per pharmacy. Healthwatch chief executive Louise Ansari expressed concern about the impact on elderly populations, noting that the closures were undermining the government's flagship Pharmacy First programme, designed to relieve pressure on GP practices by allowing patients to seek care for common conditions at local pharmacies.

The Pharmacists' Defence Association (PDA) has written to the National Pharmacy Association (NPA) to highlight several important points regarding their proposed "day of action" on 20 June 2024. The NPA describes this initiative as a response to the "emergency across the community pharmacy sector." In a letter addressed to NPA Chair Nick Kaye and Chief Executive Paul Rees, the PDA's director of pharmacy, Jay Badenhorst stressed the need for NPA members to consider their obligations to staff and patients before participating in the planned actions. He stated, "We are supportive of a new contractual framework for the community pharmacy sector." "However, any actions taken must ensure the safety of patients and the operational integrity of pharmacies." The PDA's letter also expressed concerns over the safety and operational impact of the proposed symbolic gestures, including turning off lights and blacking out windows.

Community pharmacy is integral to accelerating the three shifts envisaged by the government, but concrete action is needed to address the current funding crisis - the Company Chemists' Association (CCA) has stated in its response to the 10-year plan consultation. The CCA highlighted a wide range of pharmacy services that could contribute to achieving the government's vision shifting care from hospitals to community, from analogue to digital, and from treating sickness to prevention. To strengthen the sector's role in prevention, it proposes expanding the pharmacy's role in vaccination, screening, emergency hormonal contraception (EHC), and smoking cessation services. Furthermore, the CCA's submission noted that the expansion of Pharmacy First as "key to moving more care into the community."

The Company Chemists' Association (CCA) has urged NHS England to expand the Pharmacy First service by increasing treatment options, adding more conditions, and integrating Independent Prescribing into the service. This would further promote pharmacists as antimicrobial stewards while enhancing patient access to urgent care, it said. Managing patient demand for antibiotics remains a challenge for healthcare professionals, including pharmacists. However, a new report by CCA confirms that pharmacists are acting as responsible providers of antibiotics, in line with Antimicrobial Resistance (AMR) guidelines. The service allows pharmacies to provide advice and treatment, including prescription-only medication, for seven common conditions: earache, uncomplicated urinary tract infections (UTIs) in women, sore throat, sinusitis, infected insect bites, impetigo, and shingles. Patients can access the service via GP referrals or by visiting or contacting a pharmacy directly.

Hobbs, who joined the company in 2019, navigated it through the challenges of the COVID-19 pandemic, and successfully oversaw the acquisition and integration of Lexon in 2023. He will retire from the company at the end of September 2024. "After five years with the company, I am retiring at the end of September to spend time with my wife who was diagnosed with motor neurone disease last year," Hobbs said. "I wish to extend my personal thanks to our owners, the Bestway Group, for their kindness and understanding of our situation. "It has been a privilege to lead the Well Pharmacy, now Bestway Healthcare organisation. The business is resilient for today and fit to prosper in the long term. When I leave it will be with gratitude and admiration for the 7,500+ people in Bestway Healthcare who are committed to improving the lives of our patients and customers, thank you all."